Literature DB >> 24446063

Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity.

Romain Eschalier1, Patrick Rossignol, Anna Kearney-Schwartz, Chris Adamopoulos, Kyparissi Karatzidou, Renaud Fay, Damien Mandry, Pierre-Y Marie, Faïez Zannad.   

Abstract

Incidence and prevalence of abdominal obesity (AO) are growing exponentially. Subjects with AO are at higher risk of developing heart failure. The purpose of the study was to investigate early changes in cardiac and arterial structure and function and extracellular matrix biomarkers in normotensive healthy subjects with AO. Subjects with AO and age- and sex-matched controls underwent echocardiography, MRI (cardiac remodeling index), carotid intima-media thickness, pulse wave velocity, and blood fibrosis biomarkers measurements. We enrolled 87 subjects with AO and 53 controls. Although normotensive, subjects with AO had higher systolic blood pressure (BP; 122±11 versus 116±11 mm Hg; P=0.003), left ventricular mass (94±24 versus 84±21 g; P=0.034), and cardiac remodeling index (0.67±0.16 versus 0.60±0.10 g/mL; P=0.026) but unchanged carotid intima-media thickness and pulse wave velocity. Diastolic dysfunction (E' <10 cm/s) could be detected in 38% of subjects with AO (4% in controls). Left ventricular remodeling, as assessed by cardiac remodeling index, was positively and independently associated with higher BP (systolic BP and mean arterial pressure but not diastolic BP) and AO. Higher BP, AO, and procollagen-III-N-terminal peptide (≥2.4 ng/mL) concentrations (odds ratio, 4.15 [1.42-12.2]; P=0.01) were positively associated with diastolic dysfunction. Early cardiac structural remodeling, fibrosis, and diastolic dysfunction were detectable in healthy subjects with AO. Higher BP, procollagen-III-N-terminal peptide, and AO were independently associated with early cardiac structural and functional changes. It is to be investigated whether in subjects with AO, an early BP reduction, even if normotensive, combined with weight loss may avoid adverse cardiac remodeling and protect against progression to heart failure.

Entities:  

Keywords:  blood pressure; heart failure, diastolic; obesity, abdominal; procollagen; ventricular remodeling

Mesh:

Substances:

Year:  2014        PMID: 24446063     DOI: 10.1161/HYPERTENSIONAHA.113.02419

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

1.  High-fat diet induced central adiposity (visceral fat) is associated with increased fibrosis and decreased immune cellularity of the mesenteric lymph node in mice.

Authors:  Aaron M Magnuson; Daniel P Regan; Andrea D Booth; Josephine K Fouts; Claudia M Solt; Jessica L Hill; Steve W Dow; Michelle T Foster
Journal:  Eur J Nutr       Date:  2019-06-04       Impact factor: 5.614

2.  Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort.

Authors:  Kénora Chau; Nicolas Girerd; Martin Magnusson; Zohra Lamiral; Erwan Bozec; Ludovic Merckle; Margret Leosdottir; Erasmus Bachus; Zied Frikha; João Pedro Ferreira; Jean-Pierre Després; Patrick Rossignol; Jean-Marc Boivin; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2018-04-21       Impact factor: 5.460

Review 3.  Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation.

Authors:  I Barchetta; F A Cimini; G Ciccarelli; M G Baroni; M G Cavallo
Journal:  J Endocrinol Invest       Date:  2019-05-09       Impact factor: 4.256

Review 4.  Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.

Authors:  Alessia Buglioni; John C Burnett
Journal:  Clin Chim Acta       Date:  2014-10-23       Impact factor: 3.786

Review 5.  The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism.

Authors:  Yukang Mao; Kun Zhao; Peng Li; Yanhui Sheng
Journal:  Mol Cell Biochem       Date:  2022-10-10       Impact factor: 3.842

6.  Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial).

Authors:  Pavel Osmancik; Štěpán Havránek; Veronika Bulková; Jan Chovančík; Tomáš Roubíček; Dalibor Heřman; Zuzana Čarná; Vladimír Tuka; Martin Matoulek; Martin Fiala; Otakar Jiravský; Sylvie Stregl-Hruskova; Adam Latiňák; Jiřina Kotryová; Jiří Jarkovský
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

7.  One-year impact of bariatric surgery on left ventricular mechanics: results from the prospective FatWest study.

Authors:  Lisa M D Grymyr; Saied Nadirpour; Eva Gerdts; Bjørn G Nedrebø; Johannes Just Hjertaas; Knut Matre; Dana Cramariuc
Journal:  Eur Heart J Open       Date:  2021-08-20

8.  Abdominal obesity and hypertension: a double burden to the heart.

Authors:  Paweł Krzesiński; Adam Stańczyk; Katarzyna Piotrowicz; Grzegorz Gielerak; Beata Uziębło-Zyczkowska; Andrzej Skrobowski
Journal:  Hypertens Res       Date:  2016-01-21       Impact factor: 3.872

Review 9.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities.

Authors:  Michele Cavalera; Junhong Wang; Nikolaos G Frangogiannis
Journal:  Transl Res       Date:  2014-05-10       Impact factor: 7.012

Review 10.  Heart failure with preserved ejection fraction based on aging and comorbidities.

Authors:  Ying Lin; Shihui Fu; Yao Yao; Yulong Li; Yali Zhao; Leiming Luo
Journal:  J Transl Med       Date:  2021-07-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.